Equities Analysts Issue Forecasts for MNPR Q1 Earnings

Monopar Therapeutics Inc. (NASDAQ:MNPR) – HC Wainwright dropped their Q1 2025 earnings estimates for shares of Monopar Therapeutics in a report released on Tuesday, April 1st. HC Wainwright analyst S. Lee now expects that the company will post earnings per share of ($0.44) for the quarter, down from their prior estimate of ($0.35). HC Wainwright has a “Buy” rating and a $40.00 price target on the stock. The consensus estimate for Monopar Therapeutics’ current full-year earnings is ($1.65) per share. HC Wainwright also issued estimates for Monopar Therapeutics’ Q2 2025 earnings at ($0.45) EPS, Q3 2025 earnings at ($0.48) EPS, Q4 2025 earnings at ($0.52) EPS, FY2025 earnings at ($1.89) EPS, FY2026 earnings at ($1.68) EPS, FY2027 earnings at $0.72 EPS and FY2028 earnings at $2.08 EPS.

Other research analysts also recently issued reports about the stock. Jones Trading reaffirmed a “hold” rating on shares of Monopar Therapeutics in a research report on Wednesday. Piper Sandler restated an “overweight” rating and set a $76.00 price target on shares of Monopar Therapeutics in a report on Wednesday, March 19th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $44.00.

Monopar Therapeutics Price Performance

Shares of MNPR opened at $30.00 on Thursday. The business’s 50-day moving average is $38.29 and its 200-day moving average is $24.88. The company has a market capitalization of $183.39 million, a price-to-earnings ratio of -15.23 and a beta of 1.01. Monopar Therapeutics has a fifty-two week low of $1.72 and a fifty-two week high of $54.30.

Monopar Therapeutics (NASDAQ:MNPR) last issued its quarterly earnings results on Monday, March 31st. The company reported ($2.23) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.36) by ($1.87).

Insider Buying and Selling

In related news, major shareholder Tactic Pharma Llc sold 33,334 shares of Monopar Therapeutics stock in a transaction on Wednesday, April 2nd. The shares were sold at an average price of $35.00, for a total value of $1,166,690.00. Following the completion of the sale, the insider now owns 822,255 shares of the company’s stock, valued at approximately $28,778,925. The trade was a 3.90 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 34.90% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Monopar Therapeutics

Several institutional investors have recently bought and sold shares of the stock. JPMorgan Chase & Co. bought a new stake in shares of Monopar Therapeutics during the 4th quarter worth about $45,000. Geode Capital Management LLC lifted its holdings in Monopar Therapeutics by 174.4% in the 4th quarter. Geode Capital Management LLC now owns 38,596 shares of the company’s stock worth $849,000 after purchasing an additional 24,530 shares during the last quarter. ADAR1 Capital Management LLC bought a new stake in Monopar Therapeutics during the fourth quarter worth approximately $2,861,000. Point72 Asset Management L.P. acquired a new position in Monopar Therapeutics during the fourth quarter valued at approximately $3,694,000. Finally, RA Capital Management L.P. bought a new position in shares of Monopar Therapeutics in the fourth quarter valued at approximately $11,247,000. 1.83% of the stock is currently owned by institutional investors.

Monopar Therapeutics Company Profile

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.